By Babak Akhlaghi on
August 9, 2024. Patent litigation cases often read like a legal
thriller, filled with twists, turns, and high-stakes drama. One
recent case that exemplifies this narrative is the patent dispute
between Natera and NeoGenomics. This case, decided by the U.S.
Court of Appeals for the Federal Circuit on July 12, 2024, offers a
fascinating glimpse into the complex world of intellectual property
rights and the fierce battles in patent litigation that can ensue
over innovative technologies. Natera, Inc. v. NeoGenomics Laboratories,
Inc. Case No. 24-1324 (Fed. Cir. July 12, 2024) (Moore,
CJ; Taranto, Chen, JJ.)
The Players
Natera, Inc. and NeoGenomics are healthcare companies
specializing in oncology testing. They both produce products for
early cancer relapse detection. Natera holds two patents, U.S.
Patent Nos. 11,519,035 and 11,530,454, issued in December 2022. The
'035 patent covers methods for amplifying targeted genetic
material, like cfDNA,